semaglutide

CMS launches Medicare GLP-1 Bridge program July 2026, offering Novo Nordisk's Wegovy at $50 monthly copay. Amazon Pharmacy expands oral Ozempic access.

Novo Nordisk will present 52 abstracts on Wegovy and experimental CagriSema at European obesity congress, highlighting cardiovascular benefits and women's health data.

Novo Nordisk's 72% crash from peaks sparks debate: value trap or buying opportunity amid GLP-1 market competition from Eli Lilly.

Eli Lilly reaches $1 trillion valuation while outperforming Novo Nordisk over three years, driven by superior weight-loss drug efficacy and robust pipeline strength.

Eli Lilly's Mounjaro loses market share in India to cheaper GLP-1 generics; sales fell 16% in March. FDA approves Lilly's oral GLP-1 Foundayo.

Rani Therapeutics appoints pharma veteran Jesper Høiland as Head of Strategy, bringing 30+ years of experience in obesity and metabolic disease from roles at Novo Nordisk, Radius Health, and Ascendis Pharma.

Novo Nordisk and United Biotechnology's experimental drug UBT251 outperformed semaglutide in phase 2 trials, delivering stronger weight loss and glucose control.

Novo Nordisk wins FDA approval for Wegovy HD, a higher-dose version launching in April across 70,000+ U.S. pharmacies, despite modest stock decline.

Hims & Hers surges 40% after Novo Nordisk partnership resolves litigation, enabling authorized distribution of Wegovy and Ozempic. Stock trades under 20x forward P/E.

Hims & Hers and Novo Nordisk end legal battle, partnering to distribute weight-loss drugs via telehealth. Stock surges 48.67% despite mixed guidance.

Novo Nordisk dominates the GLP-1 market with Ozempic and Wegovy, but faces stiff competition from Eli Lilly and disappointing trial results that may limit exceptional long-term returns.